Dernièrement…

📣 Communiqué de presse : https://bit.ly/3yqFJbG
#Amoéba $ALMIB annonce un report de la conclusion d’évaluation du dossier substance active #biocide. L’Autorité maltaise s’est engagé à finaliser le rapport au cours du 4ème trimestre 2021.

📣 #Amoéba $ALMIB met à disposition le Procès Verbal de son Assemblée Générale Ordinaire et Extraordinaire du 24 juin 2021.
Disponible ici : https://bit.ly/3AqWW6t

🇫🇷 @BpifranceHub et @FRdigitale publient le 1er mapping des startups à #Impact.
💚 #Amoéba est fier d’être référencé dans la catégorie #Environnement.
Découvrez les 727 startups qui font bouger les lignes
FD 👉https://bit.ly/fd-impact
BPI 👉https://bit.ly/bpi-impact

📣 Communiqué de Presse : https://bit.ly/3gUnTaO
#Amoéba annonce la nomination de M.Philippe Dujardin en qualité d’administrateur indépendant du Conseil d’Administration, en remplacement de M.Pascal Reber pour la durée du mandat restant à courir de son prédécesseur $ALMIB

Submission of the biocide application in the USA

Information of the timetable for the other regulatory dossiers:

Chassieu (France), April 6, 2021 – 5.45 pm- AMOEBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating the risk in water and human wounds, and of a biocontrol product for plant protection, still in a development phase, has submitted today the application for approval of the biocidal active substance, the living amoeba Willaertia magna C2c Maky, and the biocidal products containing it, to the U.S. Environmental Protection Agency (U.S. EPA).

Amoéba reminds that in August 2019, it had decided to voluntarily withdraw its application for approval of the biocidal active substance, the living amoeba Willaertia magna C2c Maky, and biocidal products containing it, and to submit a new application for approval at a later stage.

During a pre-submission meeting in November 2019 between Amoéba and the U.S. EPA, requests for clarification were raised about the scientific elements that led to the withdrawal of the dossier and the way in which Amoéba planned to respond.

Amoéba was therefore able to submit a new application today, with the additional studies required by the U.S. EPA.

Once the active substance and biocidal product registrations are obtained, expected by mid- 2022 subject to approval by the US EPA, registration (notification and payment of fees) will be required at the state level, which will take about two months (except for California, which requires a full dossier evaluation of about 12 months). Once registration is obtained at the local level, marketing may be possible in the State.

Amoéba thus envisages the first sales of its biocide product in the United States from the second half of 2022, subject to a positive decision by the U.S. EPA.

Information on the timetable for other biocidal and phytosanitary regulatory dossiers:

Amoéba also provides information on the regulatory timetable for the various regulatory dossiers:

Biocide application (biocidal active substance, living Willaertia magna C2c Maky):

  • Europe: the application for approval of the active substance, submitted in 2019 (see Press Release of 12 August 2019), is currently being evaluated by the Maltese authority. Amoéba considers that the evaluation report of the authority could be available mid-2021.
  • Canada: the application for registration of the active substance and biocidal products containing it, submitted in 2019 (see Press Release of 1 February 2019) is currently being evaluated. The extension of the evaluation period (initially estimated at 24 months) is due to a request for additional information from the Canadian agency to which the company has responded. Amoéba estimates that the decision of the Canadian agency could occur before the end of 2021.

Phytosanitary application (biocontrol active substance, lysate of Willaertia magna C2c Maky):

  • Europe: the application for approval of the active substance, submitted in 2020 (see Press Release of 29 May 2020), is currently being evaluated by the Austrian authority. Amoéba considers that the evaluation report of the authority could be available at the end of 2021.
  • United States: the application for registration of the active substance and products containing it, submitted in 2020 (see Press Release of 1 October 2020) is currently being evaluated. The decision of the American agency should occur during 2022.
  • Brazil: an experimental permit was obtained in February 2021, allowing the Company to initiate field trials on soybean, coffee and banana. Such trials in Brazil are required for an application file.

Details of the procedures are available in the Universal Registration Document (URD) filed with the French Financial Markets Authority (Autorité des Marchés Financiers) on 30 April 2020 under number D20-0416, in particular in sub-section 5.4.3. The URD is available on the company’s website and its update, including the above information, will be published in April 2021.